AVITA Medical, Inc. Share Price Australian S.E.

Equities

AVH

AU000000AVH4

Biotechnology & Medical Research

Delayed Australian S.E. 01:30:23 29/04/2024 BST 5-day change 1st Jan Change
2.68 AUD +2.29% Intraday chart for AVITA Medical, Inc. -3.60% -37.53%

Financials

Sales 2024 * 115M 75.5M 6.03B Sales 2025 * 164M 107M 8.56B Capitalization 337M 221M 17.63B
Net income 2024 * -56M -36.66M -2.93B Net income 2025 * -17M -11.13M -889M EV / Sales 2024 * 2.75 x
Net cash position 2024 * 19.8M 12.96M 1.04B Net cash position 2025 * 1.85M 1.21M 97M EV / Sales 2025 * 2.05 x
P/E ratio 2024 *
-6.23 x
P/E ratio 2025 *
-31.5 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+2.29%
1 week-3.60%
Current month-45.86%
1 month-44.17%
3 months-45.86%
6 months-8.84%
Current year-37.53%
More quotes
1 week
2.58
Extreme 2.58
2.85
1 month
2.58
Extreme 2.58
4.92
Current year
2.58
Extreme 2.58
5.62
1 year
2.58
Extreme 2.58
6.27
3 years
1.28
Extreme 1.28
6.27
5 years
1.28
Extreme 1.28
17.30
10 years
0.92
Extreme 0.92
17.30
More quotes
Date Price Change Volume
29/04/24 2.68 +2.29% 16 399
26/04/24 2.62 -5.42% 614,020
24/04/24 2.77 +2.97% 281,858
23/04/24 2.69 -3.24% 545,617
22/04/24 2.78 -0.71% 567,535

Delayed Quote Australian S.E., April 29, 2024 at 01:30 am

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.06 AUD
Average target price
39.74 AUD
Spread / Average Target
+204.17%
Consensus